U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23N7O
Molecular Weight 401.4652
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RISDIPLAM

SMILES

Cc1cc(-c2cc(=O)n3cc(ccc3n2)N4CCNC5(CC5)C4)nn6cc(C)nc16

InChI

InChIKey=ASKZRYGFUPSJPN-UHFFFAOYSA-N
InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C22H23N7O
Molecular Weight 401.4652
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Jun 26 16:10:17 UTC 2021
Edited
by admin
on Sat Jun 26 16:10:17 UTC 2021
Record UNII
76RS4S2ET1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RISDIPLAM
INN   USAN  
Official Name English
RO-7034067
Code English
RG-7916
Code English
RO7034067
Code English
RISDIPLAM [USAN]
Common Name English
RG7916
Code English
EVRYSDI
Brand Name English
RISDIPLAM [INN]
Common Name English
(7-(4,7-DIAZASPIRO(2.5)OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO(1,2-B)PYRIDAZIN-6-YL)PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Systematic Name English
RISDIPLAM [WHO-DD]
Common Name English
4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE, 7-(4,7-DIAZASPIRO(2.5)OCT-7-YL)-2-(2,8-DIMETHYLIMIDAZO(1,2-B)PYRIDAZIN-6-YL)-
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/19/2145
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
FDA ORPHAN DRUG 548116
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
Code System Code Type Description
INN
10614
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
PRIMARY
CAS
1825352-65-5
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
PRIMARY
EVMPD
SUB193759
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
PRIMARY
NCI_THESAURUS
C167001
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
PRIMARY
RXCUI
2390935
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
PRIMARY
DRUG BANK
DB15305
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
PRIMARY
FDA UNII
76RS4S2ET1
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
PRIMARY
PUBCHEM
118513932
Created by admin on Sat Jun 26 16:10:17 UTC 2021 , Edited by admin on Sat Jun 26 16:10:17 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> INHIBITOR
IN VITRO
TRANSPORTER -> SUBSTRATE
IN VITRO
WEAK
EXCRETED UNCHANGED
FECAL
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
IN VITRO
WEAK
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IN VITRO
METABOLIC ENZYME -> SUBSTRATE
MAJOR
EXCRETED UNCHANGED
URINE
OFF TARGET->NON-INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INDUCER
SMN2 Gene Splicing Modifier for the treatment of Spinal Muscular Atrophy (SMA)
EC50
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC AT STEADY-STATE